day 2: track 2, patient’s role, dave leventhal (pfizer) jane larkindale, jeffrey sherman,
Published 8 years ago • 183 plays • Length 41:39Download video MP4
Download video MP3
Similar videos
-
7:36
introducing remission - type 2 diabetes
-
0:47
cll highlights from ash: the phase iii amplify trial
-
0:53
glp-1 agonists and sglt-2 inhibitors for treating adults with scd and nephropathy
-
2:10
new approaches to upfront therapy in ph all
-
2:25
a phase ii adaptive study of dasatinib and inotuzumab-based induction for newly diagnosed ph all
-
2:43
24-hour urine testing does not add value to multiple myeloma response assessments
-
3:08
current driving restrictions after week 4 post-car t-cell therapy appear unnecessary
-
2:28
machine learning derived three-parameter prognostic model for survival in patients with bpdcn
-
2:59
latest clinical needs across neurological disorders.
-
2:38
@clinicalnavigator parkinson’s disease research: new hope with pna5 protein! 🧠✨
-
3:30
latest advances in the management of richter’s transformation and future outlooks
-
4:43
an individualized sequential allosct approach in patients with r/r aml or hr-mds with active disease
-
1:35
key predictors of success when administering car-t for dlbcl
-
14:50
the hope of cancer treatment: insights from dr. david agus
-
1:01:25
clinician track-diagnosis & management of inherited blood disorders in low medium resource countries
-
17:51
gasgasgas - viva - co2 journey, intracranial pressure and neonatal physiology
-
3:20
the management of patients with r/r aml who develop resistance to idh inhibitors
-
0:33
explain why it is safe to use radioisotopes to diagnose medical problems.
-
2:47
first-in-human phase i study of sar442257, a tri-specific antibody, in r/r multiple myeloma and nhl